Skip to main content
. 2019 Jan 7;10(2):140–144. doi: 10.3892/br.2019.1183

Table I.

Demographics and clinical characteristics of the study population.

Variable No. (n=72)
Age (years) 47 (36–53)
Sex, female [n (%)] 14 (19.4)
MSM [n (%)] 40 (56)
Time since HIV diagnosis (months) 122 (59–200)
Current CD4+ T-cell count (cells/µl) 605 (409–789)
HIV viral load <50 copies/ml [n (%)] 59 (82)
Time on cART (months) 72 (31–191)
Current use of PI [n (%)] 27 (37.5)
Current use of TDF [n (%)] 57 (79.2)
Current use of raltegravir [n (%)] 10 (13.9)
BMI (kg/m2) 24 (22–26.6)
Current smoking [n (%)] 26 (36.1)
Hepatitis C coinfection [n (%)] 6 (8.3)
Diabetes mellitus [n (%)] 5 (6.9)
Hypertension [n (%)] 13 (18.1)
Dyslipidemia [n (%)] 22 (30.6)
Framingham risk score (%) 4.5 (1–11.2)
eGFR (ml/min/1.73 m2), based on CKD-EPI formula 96.9±18.5
Proteinuria [n (%)] 23 (32)
Microalbuminuria [n (%)] 18 (25)
hs-CRP (ng/ml) 0.18 (0.07–0.47)
ANGPTL2 (ng/ml) 2.09 (1.45–3.03)
sCD14 (ng/ml) 1,969 (1,747–2,292)

Data are mean ± standard deviation or median (interquartile range), unless otherwise specified. ANGPTL2, angiopoietin-like protein 2; BMI, body mass index; cART, combination antiretroviral therapy; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; hs-CRP, highly sensitive-C reactive protein; MSM, men having sex with men; PI, protease inhibitor; sCD14, soluble CD14; TDF, tenofovir.